RFC
WINT

Russell Frank Company’s Windtree Therapeutics Inc WINT Stock Holding History

Russell Frank Company’s Portfolio WINT Stock Details WINT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-19
Closed – – 3518
2013
Q2 		$0 Buy
+19
New +$468 ﹤0.01% 3390

Other funds holding WINT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Russell Frank Company's WINT Position: Q3 2013 in Review

Russell Frank Company sold out of Windtree Therapeutics Inc (WINT) in Q3 2013, closing a stake of 19 shares.

Russell Frank Company first reported a position in WINT in Q2 2013 and held it in 1 quarter. The position peaked at $0 in Q2 2013. 50 funds tracked by Wall St. Rank hold WINT as of Q3 2013.

  • Russell Frank Company reported no remaining Windtree Therapeutics Inc position as of Q3 2013 after selling out during the quarter.
  • Russell Frank Company sold 19 Windtree Therapeutics Inc shares in Q3 2013.
  • Russell Frank Company first reported a position in Windtree Therapeutics Inc in Q2 2013 and held it in 1 quarter.
  • Russell Frank Company's Windtree Therapeutics Inc position peaked at $0 in Q2 2013.
  • 50 funds tracked by Wall St. Rank held Windtree Therapeutics Inc as of Q3 2013.

Based on Russell Frank Company's 13F filing for Q3 2013, filed 29 Oct 2013.